Gland Pharma Limited Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated May 14, 2026 3 min read

Gland Pharma enters its Q4 FY26 earnings print amid a significant leadership transition and a strategic push to transform into a high-end, innovation-driven CDMO. Retail investors will be watching for updates on the Cenexi turnaround trajectory and the company's ability to maintain its gross margin profile against a backdrop of evolving GLP-1 capacity utilization.

Quick Details

Results date	May 15, 2026
Quarter	Q4 FY 2025-2026
Previous quarter revenue	Rs. 16,954 Mn
Previous quarter PAT	Rs. 2,797 Mn
Previous quarter EBITDA margin	26%
Market cap	Rs. 30,447 Cr
CMP	Rs. 1,848.0

Gland Pharma Limited Q4 Results Date and Time

The board will meet on May 15, 2026, to consider the audited financial results and recommend final dividend for FY26.

An investor call is scheduled for May 15, 2026.

What to expect from Gland Pharma Limited's Q4 FY26 results

In its most recently reported quarter, Gland Pharma posted revenue of Rs. 16,954 Mn, PAT of Rs. 2,797 Mn, and an EBITDA margin of 26%. The company is targeting mid-teens revenue growth for FY26, supported by the ramp-up of its complex injectables portfolio and a 15% organic CAGR target over the next 5 years. Management continues to focus on the Cenexi turnaround, aiming for a EUR 50 million revenue run rate to achieve EBITDA break-even. The upcoming call will likely address the impact of recent leadership changes, including the resignation of the CEO effective April 30, 2026, and the progress of ongoing contract discussions with insulin and GLP-1 players.

Key Things To Watch

Performance vs Guidance Tracking

FY26 Mid-teens Revenue Growth — 12% growth achieved in 9M FY26
Cenexi Break-even — Targeting EBITDA positive status from Q3 FY26 onwards
Gross Margin Sustainability — Target range of 74-75% confirmed by management

Strategic Updates

CEO Transition — Update on the appointment of a new CEO following the resignation of Mr. Shyamakant Giri
GLP-1 Pipeline — Progress on negotiations with 7-8 GLP-1 customers and a major insulin player
Cenexi Turnaround — Confirmation of EUR 50 million revenue run rate and path to profitability

Operational Focus

R&D Investment — Normalization of R&D spend toward the ~5% of revenue target
RTU Bag Portfolio — Development status of 13 products addressing a $685 million market opportunity
Capex Progress — Execution of the Rs. 2,000 crore investment plan

Frequently Asked Questions

When will Gland Pharma announce Q4 FY 2025-2026 results?

Gland Pharma is scheduled to announce its Q4 FY 2025-2026 results on May 15, 2026.

Will Gland Pharma announce a dividend with these results?

Yes, the board is scheduled to meet on May 15, 2026, to consider the audited financial results and recommend a final dividend for FY26.

What was Gland Pharma's revenue in its previous quarter?

Gland Pharma reported revenue of Rs. 16,954 Mn in Q3 FY26.

When does Gland Pharma expect Cenexi to break even?

Management targeted reaching a EUR 50 million revenue run rate by Q3 FY26 to achieve EBITDA positive status.

Is Gland Pharma on track with its FY26 revenue growth guidance?

The company is on track, having reported 12% revenue growth in 9M FY26 against its mid-teens target for the full year.